title: Low-dose ASA response using the PFA-100 in women with high-risk pregnancy.
abstract: OBJECTIVE
  To study the platelet function response to low-dose ASA with the Platelet Function Analyzer (PFA-100) in pregnant women and to identify maternal characteristics associated with non-responsiveness.
  
  
  METHODS
  We conducted a prospective cohort study involving 87 pregnant women on ASA. The platelet function response to ASA was measured as the closure time obtained with epinephrine cartridges (CT-EPI) by the PFA-100. Non-response to ASA was defined as a CT-EPI < or =150 seconds after four weeks of therapy. Non-responders were given an escalating dose of ASA and their CT-EPI was tested again.
  
  
  RESULTS
  After four weeks of enteric-coated ASA 81 mg daily, 25/87 women (28.7%) were non-responders (95% CI 16.1 to 41.4). Among these women, a CT-EPI < or =150 seconds was found in 8/24 women (33.3%) after another four weeks of alternating ASA 81 mg and 162 mg daily. After a further four-week course of ASA 162 mg daily, a CT-EPI < or =150 seconds was found in 3/6 women (50.0%). Among the women who initially responded and who were reassessed at 24-32 weeks of pregnancy, the CT-EPI was < or =150 seconds in 9/36 (25.0%). There was no statistical difference in maternal characteristics between ASA responders and non-responders.
  
  
  CONCLUSIONS
  A significant number of pregnant women showed a lack of platelet function response to ASA 81 mg that was in most cases overcome with higher dosing. Furthermore, the prevalence of non-responsiveness increased with advancing pregnancy.
authors.affiliation: Department of Medicine, CHU Sherbrooke, Université de Sherbrooke, Sherbrooke QC.
authors.forename: Nadia
authors.initials: N
authors.lastname: Caron
authors.affiliation: Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal QC.
authors.forename: Georges-Étienne
authors.initials: GÉ
authors.lastname: Rivard
authors.affiliation: Department of Obstetrics and Gynecology, CHU Sainte-Justine, Université de Montréal, Montreal QC.
authors.forename: Nicole
authors.initials: N
authors.lastname: Michon
authors.affiliation: Department of Obstetrics and Gynecology, CHU Sainte-Justine, Université de Montréal, Montreal QC.
authors.forename: Francine
authors.initials: F
authors.lastname: Morin
authors.affiliation: Department of Medicine, CHU Sherbrooke, Université de Sherbrooke, Sherbrooke QC.
authors.forename: Danielle
authors.initials: D
authors.lastname: Pilon
authors.affiliation: Department of Obstetrics and Gynecology, CHU Sherbrooke, Université de Sherbrooke, Sherbrooke QC.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Moutquin
authors.affiliation: Department of Obstetrics and Gynecology, CHU Sainte-Justine, Université de Montréal, Montreal QC.
authors.forename: Évelyne
authors.initials: É
authors.lastname: Rey
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D010979:Platelet Function Tests / Q000295:instrumentation / Q000379:methods; D011247:Pregnancy; D018566:Pregnancy, High-Risk / Q000097:blood* / Q000187:drug effects*; D011446:Prospective Studies
chemical_list: D001241:Aspirin